A REMINDER of what the BRITISH MEDICAL JOURNAL wrote about the ‘vaccine trials’ at the beginning of the rollout.

Many of these points have become very clear since You are welcome to add your own ‘What The Fuck’ after all these statements. They are devastating.

One particularly to look out for is the warning near the end that there were concerns over subsequent – in order words post jab – exposure to coronaviruses ‘that cause the common cold’.

Vaccine trial limitations

A key limitation of the data is THE SHORT DURATION OF SAFETY AND EFFICACY FOLLOW UPTrials WERE NOT SUFFICIENTLY POWERRED TO DETECT LESS COMMON ADVERSE EVENTS RELIABLY , and the median follow-up time WAS ONLY 2 MONTHS AFTER THE SECOND DOSE.

Trials DO NOT ADDRESS WHETHER THE VACCINE PREVENTS TRANSMISSION OR AFFECTS INFECTIOUSNESS, and the duration of protection is YET TO BE DETERMINED.

There are NO DATA ON CHILDREN OR YOUNGER ADOLESCENTS, PREGNANT OR BREASTFEEDING WOMEN OR IMMUNOCOMPROMISED PEOPLE.

There are also NO DATA TO ASSESS EFFICACY IN POPULATIONS AT HIGH RISK OF SEVERE DISEASE, IN PEOPLE PREVIOUSLY AFFECTED WITH SARS-COV2, AGAINST LONG-TERM EFFECTS OF DISEASE, OR AGAINST MORTALITY.

There are concerns that the trials WERE NOT DESIGNED TO DETECT A REDUCTION IN ANY SERIOUS OUTCOME SUCH AS HOSPITAL ADMISSIONS, USE OF INTENSIVE CARE, OR DEATHS, OR WHETHER THE VACCINE CAN INTERRUPT TRANSMISSION OF THE VIRUS – – two key primary end points in vaccine efficacy trials.[

Also, since the trials have been published, important questions about final efficacy data exclusions, as well as concerns about the use of pain and fever medications, unblinding, and primary event adjudication committees have been raised.

Planned long-term follow-up of participants is unlikely to occur in the context of trials due to the ethics of following a placebo recipient long-term without offering the vaccine. This could inadvertently threaten ongoing vaccine research that is yet to define immunological correlates of protection against COVID-19, which could vary according to the vaccine platform, individual characteristics, age groups, and population subset.

Previous trials of coronavirus vaccines identified cellular immunopathology and antibody-dependent enhancement (ADE) as potential safety issues.

There are concerns over ADE of SARS-CoV-2 due to subsequent exposure to wild-type SARS-CoV-2 post vaccination and prior exposure to other coronaviruses (SUCH AS THOSE THAT CAUSE THE COMMON COLD).

Available data do not indicate a risk of vaccine-enhanced disease with the mRNA vaccines; however, data are limited and the risk over time, potentially associated with waning immunity, remains unknown and needs to be evaluated further.

0 comments

ActiveWrite a comment…

Active